Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRX 4310

Drug Profile

IRX 4310

Alternative Names: AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310

Latest Information Update: 19 Apr 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan; Ligand Pharmaceuticals
  • Developer Allergan; Io Therapeutics
  • Class Antipsoriatics; Benzoic acids; Thiophenes
  • Mechanism of Action Retinoic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neutropenia
  • Discontinued Acne; Atopic dermatitis; Psoriasis; Xerostomia

Most Recent Events

  • 19 Apr 2016 No recent reports on development identified - Preclinical for Neutropenia (Chemotherapy-induced) in USA (PO)
  • 06 Oct 2011 Discontinued - Phase-II for Acne in United Kingdom (unspecified route)
  • 06 Oct 2011 Discontinued - Phase-III for Atopic dermatitis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top